Scholar Rock Holding (NASDAQ: SRRK) — Perfil da empresa, notícias e dados financeiros
Scholar Rock is a biopharmaceutical company focused on developing innovative therapies targeting growth factor regulation for serious diseases.
Scholar Rock Holding
Scholar Rock (NASDAQ:SRRK) is a biopharmaceutical company focused on the discovery and development of innovative medicines specifically designed to regulate the growth factor activation in the disease microenvironment. The company's pipeline is rich with projects targeting serious diseases such as spinal muscular atrophy, cancer, and fibrosis, showcasing its commitment to addressing unmet medical needs. With a strategic approach to drug development, Scholar Rock aims to revolutionize treatments by honing in on novel mechanisms of action. Its objectives center around advancing research and development to bring transformative therapies from the lab to the patients who need them most.
Resumo
Operações
Produtos e/ou serviços de Scholar Rock Holding
- SRK-015, a first-in-class therapy aimed at treating Spinal Muscular Atrophy by improving motor function.
- Apitegromab, designed to target and modulate the latent form of myostatin for muscle diseases.
- SRK-181, developed to overcome resistance in cancer treatments by inhibiting a specific protein.
- A research program focused on discovering and developing drugs targeting the TGFß superfamily for cancer and fibrosis.
- Collaborations with leading pharmaceutical companies to advance therapies in muscle and bone disorders.
- Proprietary platform technology enabling the selective modulation of growth factors in the TGFß superfamily for therapeutic applications.
equipe executiva do Scholar Rock Holding
- David L. HallalCEO & Chairman of the Board
- Vikas SinhaCFO & Treasurer
- Robert Keith WoodsChief Operating Officer
- Akshay Krishnadas VaishnawPresident of R&D, Member of Scientific Advisory Board and Director
- Erin MooreInterim Principal Financial & Accounting Officer
- Lisa WymanChief Technical & Quality Officer
- Mo QatananiChief Scientific Officer
- Rushmie NofsingerVice President of Corporate Affairs & Investor Relations
- Junlin HoGeneral Counsel & Corporate Secretary
- Caryn ParlavecchioChief Human Resources Officer
Últimas notícias sobre a Scholar Rock Holding
Scholar Rock advances apitegromab FDA review
United StatesScholar Rock net loss widens as biopharma giant accelerates SMA commercialization prep
United StatesScholar Rock resubmits Apitegromab BLA following successful FDA alignment on manufacturing
United StatesScholar Rock losses widen as biotech pivots toward SMA commercialization
United States
Principais indicadores financeiros
Resultados divulgados pela Scholar Rock Holding , em USD.
- Cap. de mercado
- 5,2 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -3.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -384,6 mi | -377,9 mi | |
| 0 | -252,1 mi | -246,3 mi | |
| 0 | -171,3 mi | -165,8 mi | |
| 33,2 mi | -134,4 mi | -131,6 mi |